|
|
|
|
|
Vidarabine
drug data and news
Vidarabine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Vidarabine | ||
| Brand Names/Synonyms | Adenine Arabinoside; Ara Atp; Ara-A; Ara-Atp; Ara-a Triphosphate; Araadenosine; Arabinofuranosyladenine Triphosphate; Arabinoside Adenine; Arabinosyl Adenine; Arabinosyl-Atp; Arabinosyladenine; Arabinosyladenine Triphosphate; Arasena-A; Spongoadenosine; Vidarabin; Vidarabine; Vidarabine Triphosphate; Vira-A | ||
| Indication | For treatment of chickenpox - varicella, herpes zoster and herpes simplex | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Vidarabine is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. in vitro, Vidarabine triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Vidarabine triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Vidarabine triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. | ||
| Mechanism Of Action | Vidarabine stops replication of herpes viral DNA in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. | ||
| Vidarabine News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antivirals; Antimetabolites; ATC:J05AB03; ATC:S01AD06 | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol hydrate | ||
| Chemical Formula | C10H15N5O5 | ||
| Molecular Weight | 285.257 g/mol | ||
| Smiles String | C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O.O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | -2.115 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 24-38% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Vidarabine.html http://www.rxlist.com/cgi/generic3/vidarabine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00333 | ||
| CAS Registry Number | 24356-66-9 | ||
| KEGG Compound ID | C07195 | ||
| PubChem ID | SID:174304 | ||
| PharmGKB ID | PA451876 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |